Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA

To evaluate the immune response to Hepatitis B virus in children who have been primed with HEXAVAC or INFANRIX HEXA 10 years ago.

Inclusion Criteria:

• Healthy child
• Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant
• Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 years prior to challenge dose

Exclusion Criteria:

• Receipt of more than 3 doses of any Hepatitis B containing vaccine
• History of clinical diagnosis of infection due to Hepatitis B
• History or current close contact with known carriers of Hepatitis B virus
• Prior known sensitivity or allergy to any component of HBVAXPRO
• Chronic illness / medical condition that could interfere with study conduct or completion
• Coagulation disorder that would contraindicate intramuscular injection
• Subject is pregnant
• Receipt of corticosteroids for more than 14 days in the 30 days prior to study
• Receipt of Immunoglobulins, blood or blood-derived products in the 3 months prior to study
• Planned participation in another clinical study